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Abstract
Background: Friedreich ataxia (FRDA), the most common form of recessive ataxia, is due to reduced levels of frataxin, a
highly conserved mitochondrial iron-chaperone involved in iron-sulfur cluster (ISC) biogenesis. Most patients are
homozygous for a (GAA)n expansion within the first intron of the frataxin gene. A few patients, either with typical or atypical
clinical presentation, are compound heterozygous for the GAA expansion and a micromutation.
Methodology: We have developed a new strategy to generate murine cellular models for FRDA: cell lines carrying a frataxin
conditional allele were used in combination with an EGFP-Cre recombinase to create murine cellular models depleted for
endogenous frataxin and expressing missense-mutated human frataxin. We showed thatcomplete absence of murine frataxin
in fibroblasts inhibits cell division and leads to cell death. This lethal phenotype was rescued through transgenic expression of
human wild type as well as mutant (hFXN
G130V and hFXN
I154F) frataxin. Interestingly, cells expressing the mutated frataxin
presented a FRDA-like biochemical phenotype. Though both mutations affected mitochondrial ISC enzymes activities and
mitochondria ultrastructure, the hFXN
I154F mutantpresented a more severe phenotype with affected cytosolic and nuclear ISC
enzyme activities, mitochondrial iron accumulation and an increased sensitivity to oxidative stress. The differential phenotype
correlates with disease severity observed in FRDA patients.
Conclusions: These new cellular models, which are the first to spontaneously reproduce all the biochemical phenotypes
associated with FRDA, are important tools to gain new insights into the in vivo consequences of pathological missense
mutations as well as for large-scale pharmacological screening aimed at compensating frataxin deficiency.
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Introduction
Friedreich ataxia (FRDA), the most common hereditary ataxia,
is an autosomal recessive neurodegenerative disease characterized
by progressive gait and limb ataxia associated with hypertrophic
cardiomyopathy and an increased incidence of diabetes [1,2].
FRDA is caused by reduced expression of the mitochondrial
protein frataxin [3]. The physiopathological consequences of
frataxin deficiency are a severe disruption of Fe-S cluster
biosynthesis, mitochondrial iron overload coupled to cellular iron
dysregulation, and possibly an increased sensitivity to oxidative
stress. Frataxin is a highly conserved protein which has been
suggested to participate in a variety of pathways associated with
cellular iron homeostasis [4]. However, only its essential role as a
mitochondrial iron-chaperone for iron-sulfur cluster (ISC) biogen-
esis is widely accepted. Indeed, frataxin deficiency in human,
mouse and yeast leads to severe alteration of mitochondrial and
extramitochondrial ISC proteins [5–9]. Very recently, the
bacterial frataxin has been proposed to be an iron sensor that
act as a regulator of Fe-S cluster formation [10].
The most common mutation leading to FRDA is a (GAA)n
triplet repeat expansion within the first intron of the frataxin
gene [3]. 96% of patients carry two expanded alleles which lead
to a partial transcriptional silencing, either through the formation
of a triple helix which interferes with transcriptional elongation
[11] or epigenetic changes leading to heterochromatin formation
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strongly reduced frataxin protein expression in all tissues. This
partial silencing is of importance as in multicellular eukaryotes,
frataxin is essential for embryonic development. Indeed, complete
frataxin deletion leads to early embryonic lethality in plants and
mice [13,14], to L2/L3 larval stage arrest in C. elegans [15], and to
reduced larval viability and metamorphosis failure by systemic
silencing in the Drosophila [16,17].
A small but significant number of FRDA patients (4%) are
compound heterozygous for the (GAA)n expansion and a
micromutation [18,19]. Out of the 40 pathogenic sequence
variants reported in frataxin, at least 15 missense point mutations
have been described. There are a few prevalent mutations that
result either in classical FRDA phenotype (I154F and W155R)
or an atypical clinical presentation (G130V). Isoleucine 154 is a
hydrophobic residue involved in the protein core [20,21]. The
I154F mutation has been described in six patients from four
families from South Italy [3,18,19,22]. The clinical presentation of
these patients is indistinguable from that of patients homozygous
for the expansion. The G.T transversion at nucleotide 389
leading to the G130V replacement is the most frequent missense
mutation in FRDA, found in more than ten Caucasian patients
from five families ([18,23–25] and MK unpublished data).
Although the age of onset is within the first ten years in patients
carrying the G130V mutations, disease progression is remarkably
slow. The absence of dysarthria and the persistence of knee jerks
are consistent findings in these patients. A more spastic than ataxic
gait has also been described [18,25].
Mammalian cell models are important to study the molecular
mechanisms of disease and are powerful tools for large-scale
therapeutical screening approaches. As patient’s cell line (fibro-
blasts or lymphocytes) do not express consistently the biochemical
phenotypes associated with FRDA under basal cultured condi-
tions, RNA interference [26–30] strategies have been developed to
reproduce partial frataxin deficiency in human and murine cell
lines. A few models exhibit some of the biochemical features
associated with FRDA, notably the deficiency in ISC biosynthesis
and the increased sensitivity to oxidative stress [26,28,30], but
none reproduce the mitochondrial iron accumulation seen in
patients. In the present work, we developed novel cellular models
deleted for endogenous murine frataxin and expressing a human
frataxin cDNA carrying pathogenic missense mutations resulting
in a classical (I154F) and an atypical (G130V) FRDA clinical
presentation. The models obtained are the first stable cellular
models that reproduce spontaneously all the biochemical pheno-
type associated with FRDA.
Results
Complete frataxin deletion in murine fibroblasts is not
viable and can be rescued by transgenic expression of
mFxn
Since fibroblasts of patients with mutations directly affecting
the respiratory chain are viable in cell culture, irrespective of
viability in the animal, we sought to obtain a FRDA cell model by
frataxin deletion in mouse fibroblasts. To this end, an immortal-
ized fibroblast cell line compound heterozygous for the mouse
frataxin conditional allele and the deleted allele (Frda
L3/L-) [7]
(Fig. 1A) was transfected with a fluorescent recombinase (pEGFP-
Cre) and sorted by FACS 48 hours after transfection. Most sorted
cells stopped dividing after 2–3 days in culture, became round, to
end up floating in the culture medium after 7–10 days in culture.
The genotype of the total cellular population demonstrated that
not all adherent cells were deleted for frataxin (Fig. 1B, lane 4),
while the floating cells harvested from the supernatant presented a
clear Frda
L-/L- genotype (Fig. 1B, lane 5) suggesting that complete
frataxin deletion is lethal in fibroblast.
To confirm that frataxin deletion is the cause of cell detachment
and subsequent death, we determined whether transgenic expression
of murine frataxin (mFxn) could rescue the phenotype. The mFxn
cDNA (pSG5-mFxn) was stably expressed into Frda
L3/L- cell line
(Frda
L3/L-; mFxn). Western blot analysis confirmed a three fold
increase in frataxin protein compared to endogenous levels with no
effect on the general morphology of the cell lines (data not shown).
pEGFP-Cre transfection was then performed on both Frda
L3/L-; mFxn
and control cell lines. Transfected cells were sorted by FACS one cell
per well and the clones were cultured for seven to ten days. Nineteen
clones overexpressing mouse frataxin (Frda
L3/L-; mFxn) presented a
complete deletion of the endogenous frataxin gene (Fig. 1C, clones
C10 and E2). All clones displayed normal morphology (Fig. 1D, left
panel) and growth, demonstrating that transgenic expression of
frataxin rescues the lethality associated with complete deficiency of
endogenous frataxin. Frataxin protein overexpression was confirmed
in several deleted clones (Fig. S1). Only five clones were obtained
from the cells transfected with the empty vector (Frda
L3/L-;pSG5).
These clones exhibited an abnormal morphology with a few dozen
spindle-shaped fibroblasts, which became round and barely attached
to the plate after 5–7 days of culture (Fig. 1D, right panel). These
clones clearly stopped dividing. Genotyping of the five unhealthy
clones performed on the total cell lysates (DNA extraction was
avoided due to the small amount of cells) was successful in only three
cases: the conditional Frda
L3 allele was converted into the deleted
Frda
L- allele in all three clones (Fig. 1C, clone B7). Frataxin protein
deficiencycould not be evaluated by western blot as too few cells were
available. In electron microscopy studies, apart from the retraction of
the plasma membrane leading to an organelle dense cytoplasm, no
structural anomaly in the mitochondria nor sign of necrosis or
apoptosis was detected in Frda
L3/L-; pSG5 sorted clones (Fig. S2).
Together, these results confirm the deleterious consequence of
frataxin deficiency on cell proliferation and survival.
Transgenic expression of pathological hFXN mutants
partially rescues the endogenous frataxin deficiency
We sought to use this newly developed ex vivo system as a novel
tool to generate cell models expressing a human frataxin cDNA
carrying pathogenic missense mutations. The wild type human
frataxin (hFXN) cDNA (pcDNA-hFXN) and both mutant human
frataxin cDNA (pcDNA-G130V and pcDNA-I154F) were stably
expressed into Frda




L3/L-; I154F). Quantitative RT-PCR (not shown) and western
blot analysis confirmed the expression and correct mitochondrial
targeting and maturation of the three frataxin constructs (Fig. 2A,
lanes 4, 7 and 10).
To delete the endogenous murine frataxin, pEGFP-Cre trans-
fection and clonal sorting was performed. After the sort, 13, 6 and 3




L3/L-; I154F cell lines, respectively. As a control, similar
experiments with an Frda
L3/L- cell line stably transfected with a
truncated form of hFXN (exon 1 and 2 only) resulted in no clone.
Genotyping demonstrated a complete deletion of the endogenous
murine frataxin gene for each clone, hereafter referred as hFXN,
hFXN
G130V and hFXN
I154F clones(Fig. 2B). Quantitative RT-PCR
and western blot analysis confirmed deletion of the endogenous
mouse frataxin transcript (data not shown) and absence of the
murine protein (Fig. 2A) in each clone. Western blot analysis of
mitochondria-enriched fractions of the different clones demonstrat-
ed proper maturation of the hFXN
G130V and hFXN
I154F proteins
(Fig. 2A, lanes 8–9 and 11–12, respectively). Interestingly, all I154F
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I154F protein
compared to the wild-type or hFXN
G130V proteins, correlating with
a 4–10 fold increased level of the transcript (data not shown). All
clones showed sustained growth, demonstrating that each human
construct was able to rescue the lethal phenotype.
New ‘‘humanized’’ cell models for FRDA based on the
missense mutations
All isolated clones were viable and proliferated over multiple
passages in classical culture conditions. However, compared to the
clones expressing wild type hFXN, the hFXN
I154F expressing
clones repeatedly showed a growth defect, taking a longer time to
reach confluence. This growth defect was particularly noticeable
after strong dilution of the cell line. Although consistent, the
growth defect was not sufficiently severe to cause a significant
difference over a 4-day proliferation curve (data not shown).
Interestingly, the hFXN
G130V expressing clones did not show any
growth defect. Furthermore, while the clones expressing the wild
type hFXN presented normal fibroblast morphology (Fig. 3, line
hFXN-1D12), the hFXN
G130V expressing clones displayed a
slightly altered morphology with smaller or less spread out cells
(Fig. 3, line hFXN
G130V-G4). In correlation with the growth
defect, the hFXN
I154F expressing clones displayed a very altered
morphology, with numerous small grainy rounded cells with a
retracted cytoplasm and some elongated spindle-shaped cells
(Fig. 3, lines hFXN
I154F-1D3 and hFXN
I154F-2C1). Finally,
gigantic cells reminiscent of senescence features were also observed
in the three hFXN
I154F expressing clones. These cells were spread
out and exhibited fractionated nucleus and cytosolic vacuoles
(Fig. 3, line I154F-1D3).
The ultrastructural analysis by electron microscopy of both
hFXN
G130V and hFXN
I154F clones revealed strongly altered
mitochondrial morphology with little damage to other components
of the cell. At the cellular level, the hFXN
G130V and hFXN
I154F
clones presented cytoplasmic blebbing, an ultrastructural sign
of reversible cell injury, and increased pseudopodia (Figs. 4A and
S3). While abnormal mitochondria were rare events in the wild-
type hFXN clones, several alterations of the mitochondria were
observed in the hFXN
G130V and hFXN
I154F clones. Only few
mitochondria appeared intact with normal cristae membranes,
and many showed spherical shape, either lacking cristae
membranes, exhibiting central tubular cristae or onion-shaped
inner membrane structures (Fig. 4A and S3). Interestingly, a
significant number of giant disorganised mitochondria, derived
from mitochondrial fusion, was observed in the hFXN
I154F clones.
It is important to note that some intramitochondrial electron-
dense deposits consistent with iron accumulation were detected in
both clones, often associated to the mitochondrial membranes
(Fig. 4A). While small deposits were detected in only 10% of the
hFXN
G130V cells, more than 50% of the cells in the hFXN
I154F
clones presented several mitochondria with large intramitochon-
drial deposits. Direct measurements of the iron content of
mitochondrial-enriched fraction of the different cell lines demon-
strated that the hFXN
I154F clones present a two fold iron
Figure 1. Frataxin is essential for division and survival of murine fibroblasts. A. Schematic representation of wild-type murine frataxin
allele (Frda
+), the loxP-flanked Frda exon 4 allele (Frda
L3) and the Cre-mediated deleted allele (Frda
L-). Primers used for genotyping are represented by
arrows [7]. B. Genotyping on heterozygous Frda
L3/L- cells before (lane 3) and after (lanes 4 and 5) pEGFP-Cre transfection and sort. Adherent living
cells display a Frda
L3/L-, Cre genotype (lane 4) whereas floating cells are completely deleted for frataxin (Frda
L-/L-) (lane 5). Lane 2: positive controls of
each PCR. Lane 1: negative control (no DNA). C. Genotyping of Frda
L3/L- clones after pEGFP-Cre transfection and sort. Results from one clone
transfected with an empty vector (pSG5: Frda
L3/L-; empty, clone B7) and two clones overexpressing murine frataxin (pSG5-mFxn: Frda
L3/L-; mFxn, clones
C10 and E2). First lane: no DNA (2). Second lane: positive controls of each PCR (+). D. Phase contrast microscopy on rescued Frda
L3/L- clones after
pEGFP-Cre transfection and sort. pSG5-mFxn: normal morphology of a murine frataxin overexpressing clone (Frda
L3/L-; mFxn) and deleted for
endogenous frataxin. pSG5: cells from a clone transfected with the empty vector (Frda
L3/L-; empty). Note the presence of many elongated or round
unhealthy cells. Phase contrast (206magnification), cells plated in 96-well plastic plates.
doi:10.1371/journal.pone.0006379.g001
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absorption spectroscopy, the iron content of the soluble mito-
chondrial fraction showed a slight but not significant increased in
iron content (Fig. S4). However, the iron content of the insoluble
membrane pellet of the hFXN
I154F clones was 2.3 fold higher
compared to the hFXN clones (Fig. S4), further supporting that
the electron-dense deposits correspond to iron rich aggregates.
As a loss of cristae membranes has been described for human cell
that are devoid of mitochondrial DNA (rho
0 cells), we checked the
integrity of mitochondrial DNA by long-range PCR. No difference
was found between the hFXN and mutant clones (data not shown),
indicating that these cells did not loose their mitochondrial DNA.
To assess the consequences of the missense mutations on the
ISC-related function of frataxin, the activities of mitochondrial,
cytosolic and nuclear ISC containing enzymes known to be
decreased in FRDA heart biopsies [5] or FRDA conditional mouse
models [7–9] were measured. Both hFXN
G130V and hFXN
I154F
clones showed a significant decrease in the mitochondrial
succinate dehydrogenase (SDH) activity with a more severe effect
in the hFXN
I154F mutants compared to the hFXN
G130V mutants
with 36% and 54% residual SDH activity, respectively (Fig. 5A).
The activity of the aconitases was also decreased in both
hFXN
G130V and hFXN
I154F clones, although to a lesser degree
than the SDH activity, with 74% and 64% residual aconitase
activity, respectively (Fig. 5A). The iron regulatory protein 1
(IRP1) is a bifunctional ISC protein located in the cytosol [31]. In
the presence of [4Fe-4S] cluster, it functions as an aconitase.
Devoid of its ISC, it binds to specific mRNA stem loop structures
called IRE to regulate the expression of proteins involved in
iron homeostasis. An increase in the IRE binding activity of
IRP1 was measured only in the hFXN
I154F clones compared to
the parental cells (Fig. 5B). To determine whether there was a
deficit in a nuclear ISC protein, we evaluated the activity of Nth1,
a [4Fe-4S] glycosylase/AP-lyase involved in the base excision
repair of oxidized bases such as thymine glycol (Tg) [32]. A
significant decrease in the activity of Nth1was observed specifically
in the hFXN
I154F clones (Fig. 5C). The change in activity was not
due to a transcriptional regulation, as RT-PCR showed no
difference in Nth1 expression between the different clones (data
not shown). Note that the decrease in the ISC enzymes activities
described above occurs spontaneously, without the addition of
exogenous stress. Furthermore, the severity of the deficit was
variable from one clone to another. Finally, not all ISC enzymes
were affected in the hFXN
I154F clones. Indeed, glutamine
phosphoribosylpyrophosphate aminotranferase (GPAT), an en-
zyme of purine biosynthesis which requires the incorporation of
a [4Fe-4S] cluster to generate the mature enzyme [33], is not
affected in both the hFXN
G130V and hFXN
I154F clones (Fig. 5D),
suggesting that some ISC enzymes are less sensitive to frataxin
functional impairment.
A recognized characteristic of frataxin deficiency is the
increased susceptibility to induction of endogenous or exogenous
oxidative stress in FRDA patient cells, and in yeast, C.elegans and
Drosophila models [4,34]. To investigate the oxidative status of the
newly developed cell models, we monitored the presence of
intracellular ROS (peroxides and peroxynitrite anion) using the
dihydrorhodamine 123 probe. Comparison of oxidation-induced
fluorescence of the probe by FACS between hFXN, hFXN
G130V
and hFXN
I154F clones revealed no difference in the production of
ROS in normal culture conditions (Fig. 6A). However, the
hFXN
I154F clones were more sensitive to exogenous stress, as a
treatment with 10 mM hydrogen peroxide caused a drastic change
in fluorescence level in hFXN
I154F clones compared to moderate
effects on hFXN and hFXN
G130V clones (Fig. 6A). Furthermore,
the hFXN
I154F-2C1 clone had a lower susceptibility to stress than
the hFXN
I154F-1D3 clone since the fluorescence peak in the later
was fully shifted. This hFXN
I154F-2C1 clone appeared globally less
affected than the two others hFXN
I154F clones (1D3 and C6).
Interestingly, both hFXN
G130V and hFXN
I154F clones displayed a
significantly reduced catalase activity (44% and 51%, respectively,
Fig. 6B) that correlated with a decrease in catalase expression at
the protein level (Fig. 6C) and at the mRNA level (not shown). On
the other hand, no significant change was observed in the activity
of glutathione reductase (Fig. 6B). Furthermore, no difference in
the mitochondrial superoxide dismutase (Sod2) expression at the
protein level (Fig. 2A) or at the RNA level (data not shown) was
observed. Overall, these results suggest that the combination of
iron deregulation with a deficit in the antioxidant enzyme catalase
could explain the susceptibility to exogenous oxidative stress
observed for the hFXN
I154F clones.
Discussion
In the present study, we report the first cellular models for
FRDA based on pathological missense mutations which sponta-
neously show all the biochemical features of the human disease.
Using a fluorescent Cre recombinase in fibroblasts carrying the
conditional frataxin allele, we first demonstrated that complete
frataxin deficiency in a fibroblast cell line does not sustain cell
division and survival. Both transgenic expression of murine (mFxn)
and human frataxin (hFXN) can rescue this lethality. Through
this novel in vitro system, we generated two humanized cell models
Figure 2. Murine frataxin (mFxn) deficiency and human frataxin
(hFXN)expressionin themissensemutants.A. Western Blot analysis
on mitochondria-enriched fractions using anti-frataxin (R1270 and 1G2)
andanti-MnSOD antibodies.hFXN and mFxn lanes correspond to COS cells
transfected with wild-type human and murine frataxin expression vector,
respectively.The R1270 antibody was designed againstmurinefrataxin but
cross-reacts with the human protein. The 1G2 antibody recognizes only
human frataxin. Murine and human frataxin were separated using a long
SDS-PAGE gel. Note that murine frataxin was detected as a two-band
signal in Frda
L3/L- fibroblasts. B. Genotyping on heterozygous Frda
L3/L- cell
populations expressing either wild type or mutant (G130V or I154F) hFXN
before (Frda
L3/L-; hFXN;F r d a
L3/L-; G130V;F r d a
L3/L-; I154F) and after (hFXN, G130V
and I154F clones, three different clones for each) pEGFP-Cre transfection
andclonal sorting. First lane: positive controls ofeachPCR (+). Last lane: no
DNA (2).
doi:10.1371/journal.pone.0006379.g002
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frataxin allele with the expression of human frataxin carrying
either the G130V or I154F missense mutations found in com-
pound heterozygous FRDA patients. Of interest, the two human-
ized cell models show different severities in their phenotype, which
correlate with the disease severity observed in FRDA patients.
As in mouse models [35,36], hFXN can fully substitute for
mFxn at the cellular level. Indeed, the hFXN clones show no
morphological or biochemical alterations. In contrast, although
both hFXN
G130V and hFXN
I154F can rescue the lethality of
complete mFxn deficient cells, the sole expression of mutated
human frataxin does not fully restore functional mitochondria.
Indeed, the hFXN
G130V and hFXN
I154F mutant clones show
degenerating mitochondria with disorganized cristae and electron-
dense deposits, and a specific deficit in mitochondrial ISC enzymes
activities, which are features characteristic of FRDA. In addition,
the hFXN
I154F clones exhibit a deficit in the nuclear ISC cluster
DNA glycosylase, Nth1, a dysregulated IRP1 IRE-binding
activity, an increased mitochondrial iron content, and an increased
susceptibility to exogenous oxidative stress. Interestingly, not all
ISC enzymes are affected equivalently by frataxin deficiency. As
previously reported in the nervous tissues of conditional frataxin
knockout mouse models [7,37] as well as in Hela cells silenced for
frataxin [30], the activity of SDH is more affected than the activity
of the mitochondrial aconitase. In addition, GPAT maturation
which requires an ISC, is not affected in the more severe
hFXN
I154F clones. This observation is in agreement with data
from the conditional mouse models that suggest a threshold effect
of ISC enzyme activities that is both tissue-specific as well as
dependent on the disease progression [8]. Indeed, the new
Figure 3. Altered morphology of frataxin mutated clones. Morphology of one normal human frataxin clone (hFXN-1D12), one G130V mutated
clone (hFXN
G130V-G4) and two I154F mutated clones (hFXN
I154F-1D3 and hFXN
I154F-2C1) were studied by phase contrast microscopy after crystal
violet staining. The scale represents 50 mm in A and 25 mm in B. n, normally spread fibroblast; ls, less spread cell; r, rounded cell; ss, spindle-shaped
cell; s, senescent cell.
doi:10.1371/journal.pone.0006379.g003
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ISC enzymes deficiency than the conditional knockout mouse
models. These results suggest that the affected tissues in FRDA
should not present a deficiency in all ISC enzymes. It will be of
interest in the future to uncover which ISC enzymes participate in
the pathology of the different tissues.
The ‘‘humanized’’ cell models developed are a valuable
addition to the available cellular models for FRDA research.
Indeed, in contrast to fibroblasts or lymphocytes cell lines from
FRDA patients, which show a large variability and a lack of
reproducibility depending on the culture conditons, the biochem-
ical phenotype of the ‘‘humanized’’ cell models is stable over
multiple passages. Furthermore, the ‘‘humanized’’ cell models
spontaneously exhibit multiple ISC enzymes deficit, while
fibroblasts from FRDA patients present an ISC enzymes deficit
only under exogenous stress [38,39]. Moreover, the hFXN
I154F
Figure 4. Ultrastructural alterations and iron status in hFXN
G130V and hFXN
I154F clones. A. Electron microscopy on hFXN (i), and hFXN
I154F
(ii–iv) clones. b, plasma membrane blebbing; g-mt, giant mitochondria; Lp, lipid droplet; mt, mitochondria; mt-Fe, electron-dense intramitochondrial
deposits; N, nucleus; os-mt, onion-shaped mitochondria; p, pseudopodia; rer, rough endoplasmic reticulum. B. Determination of iron concentration.
Total iron concentration of mitochondrial-enriched fractions of the different clones was assessed spectrophotometrically using bathophenanthroline
as described in material and methods. Results are given as mean of nmol of iron per mg of protein in each fraction + SD. * p,0.01.
doi:10.1371/journal.pone.0006379.g004
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a feature not found in FRDA fibroblasts nor lymphocytes [40–42].
A common feature between the FRDA fibroblasts and the
hFXN
I154F clones is the increased sensitivity to exogenous
oxidative stress [38,42–44]. Therefore, as both the G130V and
I154F mutant clones display a stable and spontaneous biochemical
phenotype and are able to proliferate in classical culture condi-
tions, these new cellular models will be useful for functional-based
large-scale drug screening.
The pathological missense mutations affect murine fibroblasts
in a manner that correlates with the disease severity in compound
heterozygotes. The hFXN
G130V mutant appears more efficient to
rescue lethality than the hFXN
I154F mutant although neither clone
completely rescues the phenotype. The global morphological
alterations as well as the ISC enzymes deficits are less severe in the
hFXN
G130V clones. Furthermore, the ultrastructural abnormalities
in mitochondria as well as intramitochondrial iron deposits were
more frequent in the hFXN
I154F mutants and a growth defect was
only observed in this more severe model. We observed a high
expression level of the hFXN
I154F transgene compared to the wild-
type or hFXN
G130V mutant, pointing to a severe functional
impairment of the hFXN
I154F protein. Indeed, during the clonal
selection, only cells expressing high copy number of this severe
mutant were able to undergo cell proliferation.
The increased susceptibility to exogenous oxidative stress of the
hFXN
I154F clones probably arises from strong iron homeostasis
dysregulation in conjunction with a decreased activity of the
antioxidant enzyme, catalase. Recently, Anderson et al. have
shown that ectopic expression of enzymes that scavenge H202
(peroxisomal and mitochondrial catalases and a mitochondrial
peroxiredoxin) in a Drosophila model deficient for frataxin
suppresses some of the deleterious phenotypes associated with
frataxin deficiency, while overexpression of enzymes that scavenge
superoxides (SOD1 and SOD2) have no effect [45]. The present
results further support the notion that the increased susceptibility
of frataxin deficient cells is linked to an impaired capacity to
detoxify H202, although the sole impairment of catalase is not
sufficient to result in increased susceptibility (hFXN
G130V clones).
Finally, it would be of interest to test the potential effect of catalase
mimetics on the hFXN
I154F cellular model. Indeed, a recent study
demonstrate that a catalase mimetic can restore the responsiveness
of the Nrf2-dependent signaling pathway to induced oxidative
stress in frataxin-depleted cells [40].
The genotype-phenotype correlation observed in our cell
models is not fully explained by structural and functional studies.
A comparative study of the protein dynamics of human frataxin
variants has revealed that although destabilized, both hFXN
G130V
and hFXN
I154F mutant proteins should be properly folded in
physiological conditions [46]. However, the two frataxin variants
show different iron binding properties. While the G130V mutation
decreases iron affinity of the protein, the hFXN
I154F mutant
protein precipitates in presence of iron [46,47]. The models that
Figure 5. Biochemical measurements of ISC enzyme activities in wild-type hFXN, mutant hFXN
G130V and hFXN
I154F clones. A.
Complex II of respiratory chain (Succinate Quinone DCPIP Reductase, SQDR; white bars) and aconitases (grey bars) specific activities were
standardized to isocitrate dehydrogenase (IDH) specific activity and expressed as percentage of control activity. B. IRP1/IRE binding activity was
measured by EMSA. Signals in the absence and in the presence of 2% of 2-bmercaptoethanol (bME) were quantified to determine the
percentage of IRE-binding IRP1 in each clone. C. Nth1 activity was determined by the thymidine glycol nicking activity of crude nuclear extracts
of each clone. Results, expressed as percentage of control activity, are given as the mean of the quantified intensity of Nth1 cleaved product
signal from the thymidine glycol containing oligo observed on a 20% denaturing polyacrylamide gel. D. Western blot analysis using a specific
anti-GPAT antibody. GAPDH was used as a loading control. GPAT C1F represents COS cells expressing a mutated GPAT which cannot be
maturated, giving the GPAT precursor migration size. All values were generated by determining the means of two or three independent
experiments performed on different cell extracts on at least 3 clones of hFXN, hFXN
G130V or hFXN
I154F. Data are represented as mean + SD.
*p ,0.05; *** p,0.005.
doi:10.1371/journal.pone.0006379.g005
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properties of the two mutant proteins, and to test whether the
differential in vitro iron binding property of the mutant proteins is
relevant in vivo.
In addition, our results show for the first time that complete
frataxin deficiency in a fibroblast cell line does not sustain cell
division and survival. The deficit in the activity of the respiratory
chain complexes alone may not explain the severity of the
phenotype, as fibroblasts carrying mitochondrial respiratory chain
deficiency are viable in culture. It is therefore tempting to
speculate that the phenotype associated with complete deficiency
of frataxin in fibroblast is linked to the deficit of alternative
essential ISC proteins, such as the eukaryotic primase [48],
necessary for DNA replication, and the ABCE1 protein [49],
essential for translation initiation and ribosome maturation.
Further investigations to test these hypotheses are however
difficult due to the paucity of these frataxin deficient cells.
While some pharmacological compounds have shown some
promising results in clinical trials in providing protection on
certain aspects of the disease, there is still no effective therapy for
FRDA. A valuable therapeutic approach would be frataxin
replacement either by gene therapy or by protein replacement
using protein transduction domains. We believe that the in vitro
system that we have generated will provide a powerful tool to
functionally evaluate frataxin protein delivery methods or frataxin
replacement therapeutic strategies.
Materials and Methods
Plasmid constructs, molecular analysis, and
mitochondrial-enriched fraction
The complete coding sequence (nucleotide sequence 1–624) x
of mouse frataxin (mFxn) was subcloned from the pTL1 vector
[50] to the pSG5-Puro-Flag vector (modified from pSG5 vector,
Stratagene) by enzymatic restriction. The complete coding
sequence of human frataxin (hFXN) wild-type (nucleotide
sequence 1–632), C-terminal truncated form encoding exons 1
and 2 only (nucleotide sequence 1–263) and full length hFXN
carrying the G130V and I154F missense mutations were
subcloned from the pTL1 vectors [50,51] to the pcDNA 3.1/
Zeo (Invitrogen) vector either by enzymatic restriction or PCR.
The cDNA encoding bacteriophage P1 Cre recombinase was
cloned between the BglII and EcoRI restriction sites of pEGFP-C2
(Clontech), in frame with and 39 to the EGFP cDNA. All
constructs were checked by sequencing. Genotyping was per-
formed as previously described [7]. Quantitative RT-PCR of
mouse frataxin, hprt, Sod1, Sod2, and Nth1 transcripts were
performed on a LightCycler 480 (Roche) as previously described
Figure 6. ROS determination and antioxidative enzymes activities in wild-type hFXN, mutant hFXN
G130V and hFXN
I154F clones. A.
FACS analysis of cells incubated with DHR123. The dashed curve represents the autofluorescence of fibroblasts cells without DHR123 treatment. The
black curve represents the observed fluorescence in cells in endogenous conditions and the grey curve is the fluorescence induced after hydrogen
peroxide incubation (10 mM; 30 min). Experiments were done in triplicate on 3 clones of hFXN, hFXN
G130V and hFXN
I154F. Results show one
representative diagram from one clone for hFXN and hFXN
G130V, and 2 clones for hFXN
I154F. B. Enzymatic actvities of catalase (grey bars) and
glutathione reductase (black bars) were determined spectrophotometrically. Activities are presented as the percentage of WT hFXN clones activity.
Data are represented as mean + SD. * p,0.05. C. Catalase protein was detected using an anti-catalase antibody and compared to GAPDH as a loading
control.
doi:10.1371/journal.pone.0006379.g006
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and the mouse catalase transcript was performed using primers
described in Text S1. The integrity of mitochondrial DNA was
checked by large-fragment PCR using primers (3278 and 13337)
as described [52]. Total protein extract and mitochondria-
enriched fractions obtained by digitonin treatment [53] were
analyzed on SDS-Glycine-PAGE (10–13.5% acrylamide). Western
blot and antibody dilution were as previously described [8].
Cell culture, transfection, and FACS sorting
Murine fibroblast cultures from frataxin heterozygous (Frda
L3/L-)
mice (Fig. 1A) [7] were established using the primary-explant
technique [54], and immortalized by transfection with a Large
Antigen T construct. All transfections were performed using the
Fugene 6 Transfection Reagent kit (Roche). Stably transfected
fibroblasts were grown in DMEM media (Sigma, Saint Louis,
Missouri) with 10% fetal calf serum and 50 mg/ml gentamycin,
supplemented either with puromycin (5 mg/ml) or zeocin (250 mg/
ml). Antibiotic selection was maintained for one month to obtain
stable cell lines.
Cell sorting was performed 48 hrs after transfection. Trypsin-
ised cells were resuspended in PBS and filtered through a 50
mm sterile mesh (BD Biosciences), and were then sorted for EGFP
expression on a FACSDiVa Vantage (Becton-Dickinson). EGFP
positive cells were either isolated one cell per well in 96-well
plates filled with conditional medium or collected all together
(population).
Phase contrast, crystal violet staining, and electron
microscopy
Cells were fixed with methanol and stained with crystal violet
0.1%. Living cell cultures and stained cells were observed using a
Leica DMLB inverted microscope with Hoffman contrast (LMC)
(106 magnification) or phase contrast (206 magnification) and
photographs were taken by a CoolSnap camera. For electron
microscopy, cellular clones were fixed in a freshly made mixture of
2.5% paraformaldehyde and 2.5% glutaraldehyde in cacodylate
buffer (0.1 M, pH 7.2), rinsed in cacodylate buffer, postfixed in
1% osmium tetroxide in 0.1 M cacodylate buffer for 1 hour at
4uC, dehydrated, and embedded in Epon. Ultrathin sections were
cut at 70 nm and contrasted with uranyl acetate and lead citrate
and examined with a Morgagni 268D electron microscope. Three
to five clones were analyzed from each cell line.
Biochemical analyses
The activities of the succinate dehydrogenase (SDH), aconitases
and isocitrate dehydrogenase (IDH) were as previously described
[7]. The specific activities of SDH and aconitases were reported to
the specific activity of IDH. Three independent measurements
were performed on four hFXN clones, five hFXN
G130V and three
hFXN
I154F mutant clones. Nth1 activity was assessed as described
[8]. The IPR1 IRE-binding activities were assessed by EMSA as
previously described [55] with some modifications as described in
Text S1. The activity of catalase was determined spectrophoto-
metrically as described [56] by measuring the absorbance decrease
at 240 nm in a 20 mM phosphate buffer pH 7 containing 10 mM
of hydrogen peroxide. The glutathione reductase activity assays
were carried out in phosphate buffer (pH 7.4; 0.1 M) which
contains 0.5 mM EDTA and 1 mM of oxidized glutathione at
37uC. The reaction was initiated by adding 0.2 mM of NADPH
(SIGMA). Activity was determined by following the disappearance
of NADPH at 340 nm.
Iron measurements
Mitochondrial-enriched extracts were mixed with 0.3 volume of
HCl 12N and incubated at 40uC for 1 hour. Distilled water was
added and precipitated material was removed by centrifugation at
15,000 g, 10 min. The samples were diluted with Tris-base 1 M
pH 8.8 and incubated in presence of ascorbic acid 0.25% and
bathophenanthroline disulfonic acid 0.02% (Sigma) for 1 hour in
the dark. The absorbance at 535 nm of the iron/bathophenanthro-
line disulfonate complex was measured against a blank containing
mitochondrial extract, buffer and reagents without bathophenan-
throline. The iron concentration was determined using a molar
extinction coefficient of 22,140 M
21.cm
21 for the complex [57].
For the atomic absorption spectroscopy, mitochondria-enriched
fractions were lysed with Tris 0.1 M pH 7.5, Triton X-100 0.5%
and mitochondrial soluble fraction was separated from the
membrane insoluble pellet by centrifugation 12,000 g, 10 min at
4uC. Supernatant were diluted in pure water (18 MV) containing
0.2% nitric acid. The pellets were dissolved in 1 ml of pure nitric
acid. The calibration of the iron concentration was done by using
standardironsolutionsforatomicabsorptionpurchasedfromFluka.
The graphite furnace used was a Perkin-Elmer 4110ZL spectrom-
eter equipped with an autosampler AS-72.
Reactive Oxygen Species (ROS) determination
The presence of cellular ROS was assessed by using the redox
sensitive probe DiHydroRhodamine 123 (DHR123, Molecular
Probes). Fibroblasts (60–80% of confluency) were incubated with
30 mM of DHR123 at 37uC for 15 min, washed twice with PBS
and incubated 30 min at 37uC in PBS supplemented or not by
10 mM of hydrogen peroxide. Cells were then treated with trypsin,
centrifuged at 1000 g, 5 min in culture medium and washed with
PBS. The fluorescence intensity of cells was analysed by flow
cytometric analysis in a FACScalibur (Becton-Dickinson; FL-1,
band pass filter 530/30 nm). Data were analysed by Flowjo.
Statistics
All data represent mean6SD. Statistical analyses were per-




Found at: doi:10.1371/journal.pone.0006379.s001 (0.04 MB
DOC)
Figure S1 Murine frataxin protein level in FrdaL-/L- transfect-
ed clones. Frataxin protein level in transfected clones. Western
Blot analysis of total protein extracts from FrdaL3/L- non-
transfected cell line (NT), the FrdaL3/L-; empty growing clone F8,
and four FrdaL3/L-; mFxn clones (B6, H5, C10 and E2) using a
polyclonal frataxin antibody. b-tubulin detection was used to assess
equal loading in each lane. Note that in the F8 clone, we detect
endogenous frataxin confirming its non-deleted status.
Found at: doi:10.1371/journal.pone.0006379.s002 (1.72 MB TIF)
Figure S2 Morphology of frataxin deficient clones by electron
microscopy. Frataxin deleted cells show very little ultrastructural
changes. Apart from the retraction of the plasma membrane, no
structural anomaly or sign of necrosis or apoptosis was observed in
FrdaL3/L-; empty clone (C and D) compared to FrdaL3/L-;
mFxn clone (A and B) after six days of culture. No mitochondrial
dense material suggestive of iron deposit has been observed. Lp,
lipid droplet; mt, mitochondria; N, nucleus; nu, nucleole.
Friedreich Ataxia Cell Models
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PDF)
Figure S3 Ultrastructural alterations in hFXNG130V and
hFXNI154F clones. Electron microscopy on hFXN (A),
hFXNI154F (B) and hFXNG130V (C,D) clones. b, plasma
membrane blebbing; g-mt, giant mitochondria; Lp, lipid droplet;
mt, mitochondria; mt-Fe, intramitochondrial iron deposits; N,
nucleus; os-mt, onion-shaped mitochondria; p, pseudopodia; rer,
rough endoplasmic reticulum.
Found at: doi:10.1371/journal.pone.0006379.s004 (1.76 MB TIF)
Figure S4 Iron content of hFXN, hFXNG130V and
hFXNI154F clones determined by atomic absorption spectrosco-
py. Mitochondrial soluble fraction or insoluble membrane pellet
iron contents were assessed by atomic absorption spectroscopy as
described in material and methods. Results are given as mean of
mg of iron per mg of protein in each fraction + SD. * p,0.05.
Found at: doi:10.1371/journal.pone.0006379.s005 (9.44 MB TIF)
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